申请人:Zeneca Limited
公开号:US05576334A1
公开(公告)日:1996-11-19
The invention concerns chemical compounds of formula I R.sup.1 --CON(R.sup.2)--CON(R.sup.3)--X.sup.1 --Q--X.sup.2 --GI and pharmaceutically acceptable metabolically labile esters or amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.1, R.sup.2, R.sup.3, X.sup.1, Q, X.sup.2 and G have the meanings given in the specification. The invention concerns processes for the preparation of the chemical compounds of formula I, pharmaceutical compositions containing them and their use as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa.
本发明涉及化学式I的化合物,其中R.sup.1 -CON(R.sup.2)-CON(R.sup.3)-X.sup.1-Q-X.sup.2-GI及其药学上可接受的代谢不稳定酯或酰胺,以及其药学上可接受的盐,其中R.sup.1,R.sup.2,R.sup.3,X.sup.1,Q,X.sup.2和G具有规范中给定的含义。本发明涉及制备化学式I的化合物的方法,含有它们的制药组合物以及它们作为纤维蛋白原与糖蛋白IIb / IIIa结合抑制剂的用途。